Tigecycline Dosing
For adults, administer tigecycline as a 100 mg IV loading dose followed by 50 mg IV every 12 hours over 30-60 minutes, with dose reduction to 25 mg every 12 hours only in severe hepatic impairment (Child-Pugh C); no adjustment is needed for renal impairment. 1
Standard Adult Dosing
- Loading dose: 100 mg IV administered over 30-60 minutes 1
- Maintenance dose: 50 mg IV every 12 hours over 30-60 minutes 1
- Treatment duration: 5-14 days for complicated skin/soft tissue infections and complicated intra-abdominal infections; 7-14 days for community-acquired bacterial pneumonia 1
The FDA-approved dosing is also supported by guideline recommendations for complicated intra-abdominal infections, where tigecycline 100 mg initial dose followed by 50 mg every 12 hours is listed as an acceptable regimen 2.
Hepatic Impairment Adjustments
Dose reduction is required only for severe hepatic dysfunction:
- Child-Pugh A and B (mild to moderate): No adjustment needed; use standard dosing of 100 mg loading dose, then 50 mg every 12 hours 1
- Child-Pugh C (severe): 100 mg loading dose, then reduce maintenance to 25 mg every 12 hours 1
This recommendation is based on pharmacokinetic data showing tigecycline clearance decreases from 31.2 L/h in Child-Pugh A to 13.5 L/h in Child-Pugh C patients, representing approximately 50% reduction 3. Patients with severe hepatic impairment should be monitored closely for treatment response 1.
Renal Impairment
No dose adjustment is necessary regardless of renal function. 1 Tigecycline is not significantly removed by hemodialysis, and renal clearance accounts for only 33% of total elimination 4. Research suggests the conventional 50 mg every 12 hours regimen remains effective for most infections in patients with renal impairment, though severe infections caused by less susceptible organisms (MIC >2 mg/L) may require consideration of higher doses 5.
Pediatric Dosing (Use Only When No Alternatives Available)
Tigecycline use in pediatric patients is NOT recommended due to increased mortality observed in adult trials. 1 However, if absolutely no alternative antibacterial drugs are available:
- Ages 8-11 years: 1.2 mg/kg IV every 12 hours (maximum 50 mg per dose) 1
- Ages 12-17 years: 50 mg IV every 12 hours 1
- Under 8 years: Not recommended due to effects on tooth development 1
Pediatric experience is limited to salvage therapy for extensively drug-resistant gram-negative infections, where loading doses of 1.8-6.5 mg/kg followed by maintenance of 1-3.2 mg/kg every 12 hours have been used with acceptable tolerability 6.
High-Dose Regimens for Severe Infections
While not FDA-approved, high-dose tigecycline (100 mg every 12 hours after standard loading) may be considered for severe infections with resistant pathogens (MIC >2 mg/L), particularly hospital-acquired pneumonia and infections caused by Klebsiella pneumoniae, Enterobacter cloacae, or Acinetobacter baumannii 5, 7, 8.
Research indicates that for pathogens with MIC ≤1 mg/L, standard dosing achieves adequate lung exposure, but MIC >2 mg/L requires high-dose regimens to achieve ≥90% probability of target attainment 8. High-dose tigecycline (200 mg daily) has shown mortality rates of 8.6-26% in critically ill patients compared to 8-61% with standard dosing, though this varied by infection severity 7.
Important Clinical Caveats
- Increased mortality risk: FDA black box warning exists for increased mortality with tigecycline compared to other antibiotics; reserve for situations where alternative treatments are not suitable 1
- Gastrointestinal effects: Nausea (28.5%), vomiting (19.4%), and diarrhea (11.6%) are common, particularly with higher doses 4
- Pregnancy: Use only if potential benefit justifies fetal risk; tigecycline crosses placenta and affects bone ossification 1
- No therapeutic drug monitoring: Unlike other antibiotics, routine TDM is not established for tigecycline 1